查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1494909

血糖監測系統市場至2030年的預測：按產品類型、技術、應用、分銷管道、最終用戶和地區的全球分析

Blood Glucose Monitoring Systems Market Forecasts to 2030 - Global Analysis By Product Type, Technology, Application, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2024年全球血糖監測系統市場規模為 180.2 億美元，預計預測期內年複合成長率為 6.8%，到2030年將達到 267.4 億美元。

血糖監測系統是一種目的是測量和監測糖尿病患者血糖值的醫療設備。這些系統通常包括血糖儀、試紙、自我檢查刺採血針以及提供即時血糖讀數的連續血糖監測系統。準確的監測可以幫助糖尿病患者及時調整藥物、飲食和生活方式，進而控制疾病。

根據國際糖尿病聯盟（IDF）估計，2021年約有5.37億成年人將患有糖尿病，預計到2045年這一數字將達到約7.83億。

糖尿病盛行率上升

全球糖尿病盛行率的增加是血糖監測系統市場的主要促進因素。隨著被診斷為糖尿病的人數持續增加，對有效血糖監測解決方案的需求不斷增加。定期血糖監測對於糖尿病管理非常重要，可以讓患者追蹤血糖濃度，就飲食、運動和藥物做出明智的決定，並預防併發症。糖尿病負擔的增加和人們對血糖控制重要性的認知不斷提高，促使人們採用先進的血糖監測系統。

昂貴的設備

這些先進設備通常價格昂貴，這可能會限制其可及性和採用率，特別是在價格敏感的市場和無力負擔費用的患者中。與試紙和感測器等消耗品相關的持續費用進一步增加了成本負擔。高昂的初始成本和經常性費用可能會阻止一些患者和醫療保健提供者採用先進的血糖監測技術，阻礙市場擴張。

擴大家庭醫療保健

隨著人們對糖尿病等慢性疾病的遠端監測和自我管理的偏好，對使用者友善且高度連接、可在家中輕鬆使用的血糖監測設備的需求不斷成長。透過將血糖監測系統與遠端醫療平台和行動醫療應用程式整合，患者可以與醫療保健提供者即時共用血糖值資料，促進遠距會診和個人化治療調整。家庭醫療保健服務的擴展和數位健康技術的採用預計將推動先進血糖監測系統的普及。

仿冒品

假冒設備、試紙和感測器可能會危及患者安全並導致血糖讀數不準確，導致糟糕的治療決策和負面的健康結果。仿冒品可能沒有必要的品管和監管核准，其使用可能會削弱患者對合法血糖監測系統的信心。面對假冒產品的威脅，製造商面臨保護智慧財產權和確保產品正品的挑戰。

COVID-19 的影響：

COVID-19 大流行凸顯了糖尿病遠端監測和自我管理的重要性。由於醫療機構關閉和使用機會減少，許多患者依靠家庭血糖監測來管理自己的病情。這場大流行加速了遠端醫療和遠端監測解決方案的採用，包括連網血糖監測系統。然而，疫情擾亂了供應鏈，導致產品上市和監管核准延遲，暫時影響了市場成長。

預計自我血糖監測系統產業在預測期內將是最大的。

預計自我血糖監測系統領域將在預測期內主導市場。這些系統應用廣泛、易於使用且價格實惠，因而佔據了巨大的市場佔有率。這些設備使患者可以在家中或旅途中方便地檢查自己的血糖值，使他們能夠及時做出有關糖尿病管理的決定。許多國家已經制定了自我血糖監測系統的償付政策，患者和醫療保健提供者對這些設備的熟悉程度進一步支持了它們的市場優勢。

妊娠糖尿病細分市場預計在預測期內年複合成長率最高

妊娠期間發生的妊娠糖尿病預計將成為血糖監測系統市場成長最快的區隔。由於母親年齡增加、肥胖和久坐的生活方式等因素，全球妊娠糖尿病的盛行率不斷上升，推動了此患者群體對有效血糖監測解決方案的需求。此外，人們對妊娠糖尿病早期診斷和早期管理重要性的認知不斷提高，預計將推動這一領域的快速成長。

佔有率最大的地區

預計北美將佔據血糖監測系統市場的最大佔有率。高糖尿病盛行率、完善的醫療基礎設施以及有利的血糖監測設備償付政策奠定了該地區的主導地位。主要市場參與者的存在、先進的技術力以及對糖尿病管理的關注進一步推動了北美市場的成長。

年複合成長率最高的地區：

預計在預測期內，亞太地區的血糖監測系統市場成長率最高。由於快速都市化、生活方式改變和肥胖率上升等因素，該地區糖尿病人口顯著成長，這帶來了巨大的市場機會。由於中國和印度等國家龐大的患者群體和改善的醫療基礎設施，預計將為市場成長做出重大貢獻。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球血糖監測系統市場：依產品類型

  • 自我血糖測量系統
    • 血糖值儀
    • 血糖值試紙
    • 採血針和採血裝置
  • 連續血糖監測系統
    • 感應器
    • 發送器
    • 接收器

第6章 全球血糖監測系統市場：依技術分類

  • 有創血糖監測
  • 非侵入性血糖監測

第7章 全球血糖監測系統市場：依應用

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第8章 全球血糖監測系統市場：按分銷管道

  • 零售藥房
  • 醫院藥房
  • 網路藥房

第9章 全球血糖監測系統市場：依最終用戶分類

  • 醫院和診所
  • 居家照護環境
  • 診斷中心
  • 其他最終用戶

第10章 全球血糖監測系統市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Roche Diagnostics
  • Abbott Laboratories
  • Medtronic plc
  • Dexcom, Inc.
  • Ascensia Diabetes Care
  • Johnson & Johnson
  • B. Braun Melsungen AG
  • ARKRAY, Inc.
  • Terumo Corporation
  • Ypsomed Holding AG
  • Nipro Corporation
  • Sanofi
  • Nova Biomedical
  • Trividia Health, Inc.
  • AgaMatrix, Inc.
  • Echo Therapeutics, Inc.
  • GlySens Incorporated
  • i-SENS, Inc.
  • Bionime Corporation
  • DarioHealth Corp.
Product Code: SMRC26429

According to Stratistics MRC, the Global Blood Glucose Monitoring Systems Market is accounted for $18.02 billion in 2024 and is expected to reach $26.74 billion by 2030 growing at a CAGR of 6.8% during the forecast period. Blood glucose monitoring systems are medical devices designed to measure and monitor the blood glucose levels of individuals with diabetes. These systems typically include glucose meters, testing strips, and lancets for self-testing, as well as continuous glucose monitoring systems that provide real-time glucose readings. Accurate monitoring helps diabetic patients manage their condition by facilitating timely adjustments to medication, diet, and lifestyle.

According to the estimations of the International Diabetes Federation (IDF), in 2021, around 537 million adults had diabetes and it is projected to reach around 783 million by 2045.

Market Dynamics:

Driver:

Rising prevalence of diabetes

The increasing global prevalence of diabetes is a major driver for the blood glucose monitoring systems market. As the number of people diagnosed with diabetes continues to rise, the demand for effective glucose monitoring solutions grows. Regular blood glucose monitoring is crucial for diabetes management, enabling patients to track their glucose levels, make informed decisions about their diet, exercise, and medication, and prevent complications. The rising diabetes burden, coupled with growing awareness about the importance of glucose control, is fueling the adoption of advanced blood glucose monitoring systems.

Restraint:

High cost of devices

These sophisticated devices often come with a premium price tag, which may limit their accessibility and adoption, especially in price-sensitive markets and among patients with limited financial resources. The ongoing expenses related to consumables, such as test strips and sensors, further add to the cost burden. The high upfront costs and recurring expenses may deter some patients and healthcare providers from embracing advanced glucose monitoring technologies, thus hindering market expansion.

Opportunity:

Expansion of home healthcare

With the increasing preference for remote monitoring and self-management of chronic conditions like diabetes, there is a rising demand for user-friendly and connected glucose monitoring devices that can be easily used at home. The integration of blood glucose monitoring systems with telemedicine platforms and mobile health applications enables patients to share their glucose data with healthcare providers in real-time, facilitating remote consultations and personalized treatment adjustments. The expansion of home healthcare services and the adoption of digital health technologies are expected to drive the uptake of advanced blood glucose monitoring systems.

Threat:

Product counterfeiting

Counterfeit devices, test strips, and sensors can compromise patient safety and lead to inaccurate glucose readings, potentially resulting in improper treatment decisions and adverse health outcomes. Counterfeit products may lack the necessary quality control and regulatory approvals, and their use can erode patient trust in legitimate blood glucose monitoring systems. Manufacturers face the challenge of protecting their intellectual property and ensuring the authenticity of their products in the face of counterfeit threats.

Covid-19 Impact:

The Covid-19 pandemic has highlighted the importance of remote monitoring and self-management of diabetes. With lockdowns and reduced access to healthcare facilities, many patients have relied on home-based glucose monitoring to manage their condition. The pandemic has accelerated the adoption of telemedicine and remote monitoring solutions, including connected blood glucose monitoring systems. However, the pandemic has also disrupted supply chains and led to delays in product launches and regulatory approvals, temporarily affecting market growth.

The self-monitoring blood glucose systems segment is expected to be the largest during the forecast period

The self-monitoring blood glucose systems segment is expected to dominate the market during the forecast period. The widespread availability, ease of use, and affordability of these systems contribute to their large market share. These devices enable patients to conveniently check their blood glucose levels at home or on the go, empowering them to make timely decisions about their diabetes management. The established reimbursement policies for self-monitoring blood glucose systems in many countries and the familiarity of patients and healthcare providers with these devices further support their dominant position in the market.

The gestational diabetes segment is expected to have the highest CAGR during the forecast period

The Gestational diabetes, which occurs during pregnancy, is expected to be the fastest-growing segment in the blood glucose monitoring systems market. The increasing prevalence of gestational diabetes worldwide, driven by factors such as rising maternal age, obesity, and sedentary lifestyles, is fueling the demand for effective glucose monitoring solutions in this patient population. Additionally, growing awareness about the importance of early diagnosis and management of gestational diabetes is expected to drive the rapid growth of this segment.

Region with largest share:

North America is expected to hold the largest share of the blood glucose monitoring systems market. The high prevalence of diabetes, well-established healthcare infrastructure, and favorable reimbursement policies for glucose monitoring devices contribute to the region's dominant position. The presence of key market players, advanced technological capabilities, and a strong emphasis on diabetes management further support market growth in North America.

Region with highest CAGR:

The Asia Pacific region is projected to experience the highest growth rate in the blood glucose monitoring systems market during the forecast period. The region's large and growing diabetes population, driven by factors such as rapid urbanization, changing lifestyles, and increasing obesity rates, presents a significant market opportunity. Countries like China and India, with their vast patient pools and improving healthcare infrastructure, are expected to be major contributors to market growth.

Key players in the market

Some of the key players in Blood Glucose Monitoring Systems Market include Roche Diagnostics, Abbott Laboratories, Medtronic plc, Dexcom, Inc., Ascensia Diabetes Care, Johnson & Johnson, B. Braun Melsungen AG, ARKRAY, Inc., Terumo Corporation, Ypsomed Holding AG, Nipro Corporation, Sanofi, Nova Biomedical, Trividia Health, Inc., AgaMatrix, Inc., Echo Therapeutics, Inc., GlySens Incorporated, i-SENS, Inc., Bionime Corporation and DarioHealth Corp.

Key Developments:

In October 2023, Terumo Corporation announced that it has agreed with U.S.-based Dexcom, Inc (Dexcom) to cease the distribution agreement for Dexcom's Continuous Glucose Monitoring Systems (CGM) in Japan. This decision was made in accordance with Dexcom's change in marketing strategy to shift from indirect distribution to direct sales in certain key markets, excluding the U.S.

In April 2023, Dexcom announced that the FDA cleared Stelo by Dexcom, the first glucose biosensor that doesn't require a prescription, making it easier for people with Type 2 diabetes not using insulin to access leading CGM technology.

In May 2022, Abbott announced the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people four years and older6 living with diabetes. "The FreeStyle Libre 3 system is a direct result of listening to our customers - and giving them the innovation and sensing technology they've been looking for," said Jared Watkin, senior vice president of Abbott's diabetes care business.

Product Types Covered:

  • Self-Monitoring Blood Glucose Systems
  • Continuous Glucose Monitoring Systems

Technologies Covered:

  • Invasive Blood Glucose Monitoring
  • Non-Invasive Blood Glucose Monitoring

Applications Covered:

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals and Clinics
  • Home Care Settings
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats

3.6 Product Analysis

  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Blood Glucose Monitoring Systems Market, By Product Type

  • 5.1 Introduction
  • 5.2 Self-Monitoring Blood Glucose Systems
    • 5.2.1 Blood Glucose Meters
    • 5.2.2 Blood Glucose Test Strips
    • 5.2.3 Lancets and Lancing Devices
  • 5.3 Continuous Glucose Monitoring Systems
    • 5.3.1 Sensors
    • 5.3.2 Transmitters
    • 5.3.3 Receivers

6 Global Blood Glucose Monitoring Systems Market, By Technology

  • 6.1 Introduction
  • 6.2 Invasive Blood Glucose Monitoring
  • 6.3 Non-Invasive Blood Glucose Monitoring

7 Global Blood Glucose Monitoring Systems Market, By Application

  • 7.1 Introduction
  • 7.2 Type 1 Diabetes
  • 7.3 Type 2 Diabetes
  • 7.4 Gestational Diabetes

8 Global Blood Glucose Monitoring Systems Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacies
  • 8.3 Hospital Pharmacies
  • 8.4 Online Pharmacies

9 Global Blood Glucose Monitoring Systems Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Home Care Settings
  • 9.4 Diagnostic Centers
  • 9.5 Other End Users

10 Global Blood Glucose Monitoring Systems Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Roche Diagnostics
  • 12.2 Abbott Laboratories
  • 12.3 Medtronic plc
  • 12.4 Dexcom, Inc.
  • 12.5 Ascensia Diabetes Care
  • 12.6 Johnson & Johnson
  • 12.7 B. Braun Melsungen AG
  • 12.8 ARKRAY, Inc.
  • 12.9 Terumo Corporation
  • 12.10 Ypsomed Holding AG
  • 12.11 Nipro Corporation
  • 12.12 Sanofi
  • 12.13 Nova Biomedical
  • 12.14 Trividia Health, Inc.
  • 12.15 AgaMatrix, Inc.
  • 12.16 Echo Therapeutics, Inc.
  • 12.17 GlySens Incorporated
  • 12.18 i-SENS, Inc.
  • 12.19 Bionime Corporation
  • 12.20 DarioHealth Corp.

List of Tables

  • Table 1 Global Blood Glucose Monitoring Systems Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Blood Glucose Monitoring Systems Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Blood Glucose Monitoring Systems Market Outlook, By Self-Monitoring Blood Glucose Systems (2022-2030) ($MN)
  • Table 4 Global Blood Glucose Monitoring Systems Market Outlook, By Blood Glucose Meters (2022-2030) ($MN)
  • Table 5 Global Blood Glucose Monitoring Systems Market Outlook, By Blood Glucose Test Strips (2022-2030) ($MN)
  • Table 6 Global Blood Glucose Monitoring Systems Market Outlook, By Lancets and Lancing Devices (2022-2030) ($MN)
  • Table 7 Global Blood Glucose Monitoring Systems Market Outlook, By Continuous Glucose Monitoring Systems (2022-2030) ($MN)
  • Table 8 Global Blood Glucose Monitoring Systems Market Outlook, By Sensors (2022-2030) ($MN)
  • Table 9 Global Blood Glucose Monitoring Systems Market Outlook, By Transmitters (2022-2030) ($MN)
  • Table 10 Global Blood Glucose Monitoring Systems Market Outlook, By Receivers (2022-2030) ($MN)
  • Table 11 Global Blood Glucose Monitoring Systems Market Outlook, By Technology (2022-2030) ($MN)
  • Table 12 Global Blood Glucose Monitoring Systems Market Outlook, By Invasive Blood Glucose Monitoring
  • Table 13 Global Blood Glucose Monitoring Systems Market Outlook, By Non-Invasive Blood Glucose Monitoring (2022-2030) ($MN)
  • Table 14 Global Blood Glucose Monitoring Systems Market Outlook, By Application (2022-2030) ($MN)
  • Table 15 Global Blood Glucose Monitoring Systems Market Outlook, By Type 1 Diabetes (2022-2030) ($MN)
  • Table 16 Global Blood Glucose Monitoring Systems Market Outlook, By Type 2 Diabetes (2022-2030) ($MN)
  • Table 17 Global Blood Glucose Monitoring Systems Market Outlook, By Gestational Diabetes (2022-2030) ($MN)
  • Table 18 Global Blood Glucose Monitoring Systems Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 19 Global Blood Glucose Monitoring Systems Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 20 Global Blood Glucose Monitoring Systems Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 21 Global Blood Glucose Monitoring Systems Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 22 Global Blood Glucose Monitoring Systems Market Outlook, By End User (2022-2030) ($MN)
  • Table 23 Global Blood Glucose Monitoring Systems Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
  • Table 24 Global Blood Glucose Monitoring Systems Market Outlook, By Home Care Settings (2022-2030) ($MN)
  • Table 25 Global Blood Glucose Monitoring Systems Market Outlook, By Diagnostic Centers (2022-2030) ($MN)
  • Table 26 Global Blood Glucose Monitoring Systems Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.